Progress of the development of anti-COVID-19 drugs / 药学学报
Acta Pharmaceutica Sinica
; (12): 39-51, 2023.
Article
en Zh
| WPRIM
| ID: wpr-964297
Biblioteca responsable:
WPRO
ABSTRACT
Since the outbreak of the novel coronavirus (SARS-CoV-2) disease COVID-19 (also known as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019, it has spread rapidly in worldwide. Besides developing effective vaccines, it is urgent to develop safe and effective anti-SARS-CoV-2 drugs to fight this disease. Paxlovid, molnupiravir, sotrovimab and bebtelovimab are urgently authorized by FDA have been proved to be effective against Omicron. This manuscript mainly reviews the recent progress of effective inhibitors against the virus in the world, including receptor inhibitors, antibodies, natural product inhibitors, synthetic inhibitors and broad-spectrum antiviral drugs that are effective against other RNA viruses.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Año:
2023
Tipo del documento:
Article